Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer

Cancer Research

Volumn 64, Issue 10, 2004, Pages 3599-3606

  Arnold, Nichole Boyer ^a   Ketterer, Knut ^a   Kleeff, Jörg ^b   Friess, Helmut ^b   Büchler, Markus W ^b   Korc, Murray ^a,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPROPYL 2 IMIDAZOLYL DISULFIDE; APOPTOSIS SIGNAL REGULATING KINASE 1; CASPASE 3; CASPASE 9; CISPLATIN; COMPLEMENTARY DNA; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMAD7 PROTEIN; THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROVIRUS; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; HUMANS; PANCREATIC NEOPLASMS; RNA, MESSENGER; SMAD7 PROTEIN; THIOREDOXIN; TRANS-ACTIVATORS; TRANSFECTION;

EID: 2442696750     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2999     Document Type: Article

References (67)

1. ten Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effectors in TGF-β signaling. Trends Biochem Sci 2000;25:64-70.
2. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 1997;389:631-5.
3. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997;89: 1165-73.
4. Itoh S, Landstrom M, Hermansson A, et al. Transforming growth factor β1 induces nuclear export of inhibitory Smad7. J Biol Chem 1998;273:29195-201.
5. Pulaski L, Landstrom M, Heldin CH, Souchelnytskyi S. Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-β-dependent signaling but affects Smad7-dependent transcriptional activation. J Biol Chem 2001;276:14344-9.
6. Bai S, Cao X. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-β signaling. J Biol Chem 2002;277:4176-82.
7. Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 2002;10:483-93.
8. Ferrigno O, Lallemand F, Verrecchia F, et al. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-β/Smad signaling. Oncogene 2002;21:4879-84.
9. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001;41:261-95.
10. Muller JM, Rupec RA, Baeuerle PA. Study of gene regulation by NF-κB and AP-1 in response to reactive oxygen intermediates. Methods 1997;11:301-12.
11. Gallegos A, Gasdaska JR, Taylor CW, et al. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res 1996;56:5765-70.
12. Korc M. Biology of pancreatic cancer. In: Rustgi AK, editor. Gastrointestinal cancers. London: W. B. Saunders, Co.; 2003 p. 519-28.
13. Hahn SA, Hoque AT, Moskaluk CA, et al. Homozygous deletion map at 18q21. 1 in pancreatic cancer. Cancer Res 1996;56:490-4.
14. Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999;18:5363-72.
15. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-8.
16. Kleeff J, Korc M. Up-regulation of transforming growth factor (TGF)-β receptors by TGF-β1 in COLO-357 cells. J Biol Chem 1998;273:7495-500.
17. Kornmann M, Ishiwata T, Beger HG, Korc M. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene 1997;15:1417-24.
18. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-71.
19. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 1999;59:3505-11.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
21. Raitano AB, Korc M. Tumor necrosis factor up-regulates γ-interferon binding in a human carcinoma cell line. J Biol Chem 1990;265:10466-72.
22. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of the type II transforming growth factor β receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
23. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998;14:272-6.
24. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
25. + channel function by hypoglycemia and hyperglycemia : similar phenotypes but different mechanisms. J Biol Chem 2003;278: 10417-26.
26. Vogt A, Tamura K, Watson S, Lazo JS. Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1. J Pharmacol Exp Ther 2000;294:1070-5.
27. Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001;23: 273-9.
28. Lee JU, Hosotani R, Wada M, et al. Mechanism of apoptosis induced by cisplatin and VP-16 in PANC-1 cells. Anticancer Res 1997;17:3445-50.
29. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001;31:1287-312.
30. Yokomizo A, Ono M, Nanri H, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995;55:4293-6.
31. Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 1997;57:5162-7.
32. Sasada T, Nakamura H, Ueda S, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 1999;27:504-14.
33. Nishi T, Shimizu N, Hiramoto M, et al. Spatial redox regulation of a critical cysteine residue of NF-κB in vivo. J Biol Chem 2002;277:44548-56.
34. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASKI, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275: 90-4.
35. Chen Z, Seimiya H, Naito M, et al. ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene 1999;18:173-80.
36. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606.
37. Tobiume K, Saitoh M, Ichijo H. Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol 2002;191:95-104.
38. Bishopric NH, Webster KA. Preventing apoptosis with thioredoxin: ASK me how. Circ Res 2002;90:1237-9.
39. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
40. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
41. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M. Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is over-expressed in pancreatic cancer. Biochem Biophys Res Commun 1999;255:268-73.
42. Park K, Kim SJ, Bang YJ, et al. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 1994;91:8772-6.
43. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β 1 in human prostate cancer cells. Cancer Res 1996;56:44-8.
44. Wang J, Han W, Zborowska E, et al. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 1996;271:17366-71.
45. Wyllie FS, Dawson T, Bond JA, et al. Correlated abnormalities of transforming growth factor-β 1 response and p53 expression in thyroid epithelial cell transformation. Mol Cell Endocrinol 1991;76:13-21.
46. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990;62:175-85.
47. Filmus J, Zhao J, Buick RN. Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor β-1 (TGF-β1) and alters the number and type of TGF-β 1 receptors in rat intestinal epithelial cell clones. Oncogene 1992;7:521-6.
48. Zhao J, Buick RN. Regulation of transforming growth factor β receptors in H-ras oncogene-transformed rat intestinal epithelial cells. Cancer Res 1995;55:6181-8.
49. Hartsough MT, Mulder KM. Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem 1995;270:7117-24.
50. Hartsough MT, Frey RS, Zipfel PA, et al. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem 1996;271: 22368-75.
51. Yan Z, Deng X, Friedman E. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-β receptor III. J Biol Chem 2001;276:1555-63.
52. Afrakhte M, Moren A, Jossan S, et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem Biophys Res Commun 1998;249:505-11.
53. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
54. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
55. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
56. Wagner M, Kleeff J, Friess H, Buchler MW, Korc M. Enhanced expression of the type II transforming growth factor-β receptor is associated with decreased survival in human pancreatic cancer. Pancreas 1999;19:370-6.
57. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 2001;7:2931-40.
58. Rowland-Goldsmith MA, Maruyama H, Matsuda K, et al. Soluble type II transforming growth factor-β receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002;1:161-7.
59. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
60. Arner ES, Nakamura H, Sasada T, Yodoi J, Holmgren A, Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 2001;31:1170-8.
61. Kawahara N, Tanaka T, Yokomizo A, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996;56: 5330-3.
62. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 2002; 90:1259-66.
63. Sodhi A, Singh RA. Mechanism of NF-κ B translocation in macrophages treated in vitro with cisplatin. Immunol Lett 1998;63:9-17.
64. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF κB activation. Biochem Pharmacol 2002;63:1423-30.
65. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002;2:301-10.
66. Bharti AC, Aggarwal BB. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8.
67. Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.